Transcriptomics

Dataset Information

0

Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes


ABSTRACT: Teplizumab is approved for delay of diagnosis of type 1 diabetes and modulates new onset disease. Compared to EBV seronegative patients, those who were EBV seropositive prior to treatment had a more robust response to drug in two clinical trials. We compared the phenotypes, transcriptomes, and development of peripheral blood cells before and after teplizumab treatment. Higher number of Tregs and “partially exhausted” CD8+ T cells were found in EBV seropositive individuals at the baseline in the TN10 and AbATE trials. Single cell transcriptomics and functional assays identified downregulation of NFB and other pathways after treatment in treated EBV seropositive patients. Among diabetes antigen specific CD8+ T cells, T cell receptor and mTOR signaling were also reduced. Impairments in function of adaptive immune cells were enhanced by teplizumab treatment in EBV seropositive individuals. Our data indicate that EBV can impair signaling pathways in immune cells, that broadly redirect cell differentiation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE271063 | GEO | 2024/09/25

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-08-19 | PXD042711 | Pride
2016-11-21 | GSE85531 | GEO
2016-11-21 | GSE85530 | GEO
2016-12-06 | GSE85527 | GEO
2007-08-25 | E-GEOD-2171 | biostudies-arrayexpress
2005-01-22 | GSE2171 | GEO
2008-08-28 | E-GEOD-12589 | biostudies-arrayexpress
2019-11-20 | PXD013120 | Pride
2024-10-09 | GSE197333 | GEO
2022-05-08 | GSE202366 | GEO